7th Munich Vascular Conference 2017

... where doctors meet science

07–09 December | Klinikum rechts der Isar | Munich | Germany

Chairman
Hans-Henning Eckstein
Munich, Germany

Venue
Klinikum rechts der Isar
Munich, Germany

Congress organisation
CongO GmbH
Ruffinistraße 16
80637 Munich, Germany

PROGRAMME
www.mac-conference.com
Dear friends of the MUNICH VASCULAR CONFERENCE (MAC),

It is our pleasure to invite you very cordially to the 7th MUNICH VASCULAR CONFERENCE (MAC) on 07–09 December, 2017. The 7th MAC will continue to be a platform for mutual exchange between vascular clinicians from all vascular medical specialties and colleagues from translational and basic research.

In 2016 we were able to welcome a record number of more than 600 participants. Therefore, the 7th MAC will address aortic, carotid, venous and peripheral arterial diseases again. We will present the latest advances in clinical and translational vascular research, including the newest open and endovascular technologies, biological mechanisms of atherosclerosis and the latest imaging modalities.

Do not miss the latest insights into the world of academic vascular research, represented by our world-class faculty. The 7th MAC will provide the latest news and cutting-edge approaches in the management of acute and chronic arterial and venous diseases.

We look forward to welcoming you in Munich.

Prof. Hans-Henning Eckstein
Chairman

Hans-Henning Eckstein
Head of the Department of Vascular and Endovascular Surgery
Klinikum rechts der Isar (MRI) der Technischen Universität München (TUM)
Ismaninger Strasse 22
81675 Munich, Germany

Ingo Flessenkämper
Michael Gee
Rüdiger Lange
Lars Maegdefessel
Holger Poppert
Markus Schwaiger
Wolfgang Wall
Claus Zimmer
INVITED FACULTY

Afshin Assadian, Austria
B
Marc Bailey, UK
Eva Bartels, Germany
Yvonne Bausback, Germany
Friedhelm Beyerdsdorf, Germany
Colin Bicknell, UK
Gabor Biró, Germany
Martin Björck, Sweden
Leo Bonati, Switzerland
Michel Bosiers, Belgium
Richard Brandl, Germany
Jan Brunckwall, Germany
Richard Bulbulia, UK
Laura Capoccia, Italy
Nabil Chakfé, France
Nick Cheshire, UK
Tina Cohnert, Austria
Martin Czerny, Germany
Ronald Dalman, USA
Gert J. de Borst, Netherlands
Jean Paul de Vries, Netherlands
Martin Dichgans, Germany
Per Eriksson, Sweden
Christine Espinola-Klein, Germany
Jürgen Falkensammer, Austria
Andreas Fiebig, Germany
Johannes Gahlen, Germany
Reza Ghotbi, Germany
Athanasios Giannoukas, Greece
Richard Gibbs, UK
Werner Hacke, Germany
Alison Halliday, UK
Stephan Haulon, France
Tobias Hirsch, Germany
Mihai Ionac, Romania
Houman Jalai, Germany
Michael Jones, Germany
Michael Kallmayer, Germany
Angelos Karlas, Germany
Piotr Kasprzak, Germany
Athanasios Katssarygis, Germany
Christoph Knappich, Germany
Tilo Kölbl, Germany
Ralf Kolvenbach, Germany
Igor Končar, Serbia
Kornelia Kreiser, Germany
Andreas Kühn, Germany
Mario Lescan, Germany
Christos Liapis, Greece
Jes Sanddal Lindholt, Denmark
Ian Loftus, UK
Lars Lönn, Denmark
Sumaira Macdonald, USA
Klaus Mathias, Germany
Bijan Modarai, UK
Claudia Monaco, UK
Mandy Müller, Switzerland
Achim Mumme, Germany
Jonathan Nadji, Germany
Foek Nauta, Netherlands
Florian Netzer, Germany
Achim Neufang, Germany
Philipp Nicol, Germany
Christoph Nienaber, UK
Sigrid Nikol, Germany
Vasilis Ntziachristos, Germany
Stefan Ockert, Switzerland
Klaus Overbeck, UK
Ljubica Perisic Matic, Sweden
Thomas Pröbstle, Germany
Michael Rasper, Germany
Christian Reeps, Germany
Peter Ringleb, Germany
Tobias Saam, Germany
Hendrik Sager, Germany
Natzi Sakalihasan, Belgium
Sebastian Schellong, Germany
Hubert Schelzig, Germany
Andreas Schindler, Germany
Claus-Georg Schmedt, Germany
Thomas Schmitz-Rixen, Germany
Susanne Sara Schreiber, Germany
Heribert Schunkert, Germany
Henrik Sillesen, Denmark
Thomas Stadlbauer, Germany
Daniel Staub, Switzerland
Markus Steinbauer, Germany
Anders Wanhainen, Sweden
Rolf Weidenhagen, Germany
Heiko Wendorff, Germany
Moritz Wildgruber, Germany
Thomas Wyss, Switzerland
Clark Zeebregts, Netherlands
Thomas Zeller, Germany
Alexander Zimmermann, Germany
Thomas Schmitz-Rixen, Germany
Susanne Sara Schreiber, Germany
Heribert Schunkert, Germany
Henrik Sillesen, Denmark
Thomas Stadlbauer, Germany
Daniel Staub, Switzerland
Markus Steinbauer, Germany
Anders Wanhainen, Sweden
Rolf Weidenhagen, Germany
Heiko Wendorff, Germany
Moritz Wildgruber, Germany
Thomas Wyss, Switzerland
Clark Zeebregts, Netherlands
Thomas Zeller, Germany
Alexander Zimmermann, Germany
WELCOME ............................................................................................................................................... 2
SCIENTIFIC ORGANISER .................................................................................................................... 3
INVITED FACULTY .................................................................................................................................. 4 – 5
GENERAL INFORMATION .................................................................................................................. 7 – 9
PROGRAMME OVERVIEW .................................................................................................................. 7 – 9
  Overview Scientific Sessions ........................................................................................................... 10 – 11
  Overview Mini-Symposia & Workshops ......................................................................................... 12
PROGRAMME WEDNESDAY, December 06 ....................................................................................... 14 – 15
SCIENTIFIC SESSIONS .................................................................................................................... 16 – 23
  Programme Thursday, December 07 ............................................................................................... 16 – 23
  Programme Friday, December 08 ..................................................................................................... 26 – 32
  Programme Saturday, December 09 .............................................................................................. 36 – 37
MINI-SYMPOSIA .................................................................................................................................. 38 – 39
WORKSHOPS ....................................................................................................................................... 40 – 45
KEYNOTE/SPECIAL LECTURES ......................................................................................................... 48 – 55
ACKNOWLEDGEMENTS ..................................................................................................................... 60

OFFICIAL LANGUAGE
English

FREE WIFI:
Network: mwn-events
User: MAC2017
Password: Ko4kpUFg

DATE AND VENUE
07–09 December
Klinikum rechts der Isar | Munich | Germany

Main entrance:
Klinikum rechts der Isar
Ismaninger Strasse 22
81675 Munich, Germany

Entrance plenary rooms:
Klinikum rechts der Isar
Einsteinstrasse 5
81675 Munich, Germany

SOCIAL DINNER
Join us for dinner, drinks and music at the Nightclub Bayerischer Hof, Munich
Date: Friday, December 08
Administration fee: EUR 50.00 EUR (Limited seats only)
(Registration for the social dinner is only possible in conjunction with a conference registration)
REGISTRATION FEES

Full Registration (December 07-09)
- Physicians / Industry Representatives: EUR 390.00
- Fellows, Nurses and Medical Technical Assistants (verification required 1) EUR 150.00
- Students free of charge (verification required 2): EUR 0.00

Day Registration (December 07, 08 or 09)
- Physicians: EUR 180.00
- Fellows, Nurses and MTs: EUR 75.00
- Students free of charge (verification required 2): EUR 0.00

1) The reduced registration fee is only available to participants who are currently employed as fellows (assistant physicians), nurses or medical technical assistants. Please provide proof of your current employment status. We accept ENGLISH or GERMAN verifications.

2) The reduced registration fee is only available to students who have not concluded their first study yet and who are currently enrolled at the university. Please provide proof of your current university enrollment. We accept ENGLISH or GERMAN verifications.

WORKSHOPS

Workshop registrations are only possible in connection with a registration for the Munich Vascular Conference 2017. Food and beverages are included in the registration fee.

Workshop 01: Wednesday, December 06, 2017
1-day revision course on technical skills – preparation for the European examination as a Fellow of the European Board of Vascular Surgery (FEBVS) at the UEMS
- MAC-participants: EUR 180.00

Workshop 02: Wednesday, December 06, 2017
Spezialkurs Interventionsradiologie zum Erwerb der Fachkunde – 1-day course on radiation safety – only for German participants
- MAC-participants: EUR 180.00
- Vascular surgery employees of the MRI: EUR 0.00
- Other employees of the MRI: EUR 50.00

CONGRESS SECRETARIAT
Dr. Eva Knipfer
Dr. Raphaelea Kubeck
Lisa Seitz
Nathalie Schilde
Department of Vascular and Endovascular Surgery
Klinikum rechts der Isar
Technical University of Munich
Ismaninger Strasse 22
81675 Munich, Germany
Phone: +49 (0)89 41 40 2167
Fax: +49 (0)89 41 40 48 61
E-Mail: gefaesschirurgie@mri.tum.de

GENERAL INFORMATION

ACCREDITATION

Bavarian Medical Association (BLAEK)
The 7th Munich Vascular Conference, 07-09 December 2017, is accredited by the Bavarian Medical Association (BLAEK) for 15 hours of external CME credits.

European Accreditation Council for Continuing Medical Education (EACCME®)
7th Munich Vascular Conference, Munich, Germany, 07-09 December 2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 17 European CME credits (ECMEC®s).

CONGRESS ORGANISATION

CongO GmbH
Ruffinistraße 16
80637 Munich, Germany
Contact:
Antonie Jariger
E-Mail: toniejaeger@cong-o.de
Phone: +49 89 / 23 75 74 – 65
Fax: +49 89 / 23 75 74 – 70
www.cong-o.com
### OVERVIEW SCIENTIFIC SESSIONS

#### THURSDAY

<table>
<thead>
<tr>
<th>TIME</th>
<th>Lecture Hall B</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-09.30</td>
<td>CAR 1: Asymptomatic carotid disease – how to select reliably individuals with an increased carotid-related stroke risk 09.00-10.00</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>CAR 2: Update on carotid trials and guidelines 10.00-11.00</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>COFFEE BREAK 11.00-11.30</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>CAR 3: Emergency treatment of ischemic strokes 11.30-12.40</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Special Lecture 1 12.45-13.00</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>LUNCH BREAK 13.00-14.00</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>CAR 4/PAD 1: Deciphering molecular and cellular mechanisms of atherosclerotic plaque destabilization 14.00-15.10</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>CAR 5: Carotid plaque erosion, plaque vulnerability and perspectives in functional imaging 15.40-16.35</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>COFFEE BREAK 15.10-15.40</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>CAR 6: Carotid artery stenting (CAS) - out on the track again? 16.55-18.10</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>CAR 7/PAD 8: Radiation protection and team training 2017 16.10-17.55</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>CAR 8: Short communications III: Carotid Stenosis (CAR) 16.45-18.15</td>
</tr>
</tbody>
</table>

#### FRIDAY

<table>
<thead>
<tr>
<th>TIME</th>
<th>Lecture Hall B</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-09.30</td>
<td>PAD 3: Randomized controlled trials (RCT) on critical limb ischemia (CLI) and intermittent claudication 08.30-09.30</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>PAD 4: Update on atherectomy and drug-eluting technologies 09.30-10.35</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>COFFEE BREAK 10.35-11.00</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>PAD 5: PAD - a marker disease for atherosclerosis - update on antiatherosclerotic and lipid -lowering therapy 11.00-12.15</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Special Lecture 2 12.15-12.30</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>LUNCH BREAK 12.30-13.30</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>PAD 6: New assessment tools for critical limb ischemia (CLI) 13.30-14.45</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>PAD 7: Acute limb ischemia - open or endovascular treatment? 14.45-15.40</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>COFFEE BREAK 15.40-16.10</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>PAD 8: PAD/AOR 9: Radiation protection and team training 2017 16.10-17.55</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>CAR 7/PAD 8/AOR 9: Radiation protection and team training 2017 16.10-17.55</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>AOR 10: Endoleaks type I and III – still an unresolved issue in endovascular repair 16.10-17.00</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>CAR 9: Short communications III: Carotid Stenosis (CAR) 16.45-18.15</td>
</tr>
</tbody>
</table>

#### SATURDAY

<table>
<thead>
<tr>
<th>TIME</th>
<th>Lecture Hall B</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-09.30</td>
<td>VEN 1: Endovenous therapy or open surgery for primary varicosity - what is the evidence? 9.00-10.20</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>VEN 2: Update on modern and new endovenous technologies for primary varicosity 10.20-11.15</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>COFFEE BREAK 11.15-11.45</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>VEN 3: Prevention and medical therapy of deep vein thrombosis (DVT) 11.45-12.55</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>VEN 4: Recanalization strategies in acute and chronic deep venous thrombosis 12.55-13.55</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>COFFEE BREAK 13.00-13.30</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>VEN 5: Novel concepts and insights from translational aortic aneurysm research 14.00-14.30</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>VEN 6: Carotid artery stenting (CAS) - out on the track again? 14.45-15.35</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>VEN 7: Abdominal aortic aneurysms (AAA) – genetics, guidelines and outcomes after open and endovascular repair 15.00-15.15</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>VEN 8: Endoleaks type I and III – still an unresolved issue in endovascular repair 16.00-16.30</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>FAREWELL and LUNCH 14.00-14.30</td>
</tr>
</tbody>
</table>
## OVERVIEW MINI-SYMPOSIA & WORKSHOPS

### WEDNESDAY

<table>
<thead>
<tr>
<th>TIME</th>
<th>Lecture Hall Pavillon</th>
<th>Seminar Room M2a</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00-17.30</td>
<td>Technical Skills Revision Course</td>
<td>Kurs Interventionelle Radiologie zum Erwerb der Fachkunde 9.00-16.30</td>
</tr>
</tbody>
</table>

### THURSDAY

<table>
<thead>
<tr>
<th>TIME</th>
<th>Conference room 1</th>
<th>Lecture Hall Pavillon</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30-10.00</td>
<td></td>
<td>WS 1: Atherectomy for calcified peripheral lesions – indications and techniques (SPECTRANETICS)</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td></td>
<td>WS 2: Technical tips, tricks and pitfalls for the new Zenith Alpha Abdominal EVAR Device (COOK)</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td></td>
<td>WS 3: How to perform in-situ-bypass surgery in critical limb ischemia (LE MAITRE)</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td></td>
<td>WS 4: Suture mediated LT preclosing technique / Proglide - percutaneous closing device (ABBOTT)</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td></td>
<td>WS 5: DAART: Directional atherectomy and antirestenotic therapy (MEDTRONIC)</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td></td>
<td>WS 6: Suture mediated LH preclosing technique / Proglide - percutaneous closing device (ABBOTT)</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td></td>
<td>WS 7: How to perform in-situ-bypass surgery in critical limb ischemia (LE MAITRE)</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td></td>
<td>WS 8: Endovascular options for type B aortic dissections (VASCUTEK)</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td></td>
<td>WS 9: Endovascular workflow from sizing to stent deployment (M2a: 10.00-11.30; OR: 11.30-13.00) (SIEMENS/VASCUTEK)</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td></td>
<td>WS 10: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td></td>
<td>WS 11: Carotid endarterectomy (CEA) with bovine pericardial patching (LE MAITRE)</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td></td>
<td>WS 12: Early Clot Removal and Stenting in Acute DVT (BOSTON SC.)</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
<td>WS 13: EVAR workflow from sizing to stent deployment (M2a: 10.00-11.30; OR: 11.30-13.00) (SIEMENS/VASCUTEK)</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td></td>
<td>WS 14: The management of ruptured AAA - how I do it (T Wyss)</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td></td>
<td>WS 15: How to perform in-situ-bypass surgery in critical limb ischemia (LE MAITRE)</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
<td>WS 16: Endovascular workflow from sizing to stent deployment (M2a: 10.00-11.30; OR: 11.30-13.00) (SIEMENS/VASCUTEK)</td>
</tr>
<tr>
<td>17.30-18.00</td>
<td></td>
<td>WS 17: Flaring of the Bentley BeGraft during fenestrated EVAR (BENTLEY)</td>
</tr>
</tbody>
</table>

### FRIDAY

<table>
<thead>
<tr>
<th>TIME</th>
<th>Conference room 1</th>
<th>Lecture Hall Pavillon</th>
<th>Seminar Room M2a/OR 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-09.30</td>
<td></td>
<td>WS C: Cruro-pedal bypass surgery – indications and techniques (A Neufang)</td>
<td>WS 18: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td></td>
<td>WS D: How to create an endovascular team for Hybrid ORs (J Gahlen)</td>
<td>WS 19: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td></td>
<td>WS E: Experimental vascular models and vascular biobanking (L Maegdefessel)</td>
<td>WS 20: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td></td>
<td>WS F: Modern concepts in the therapy of chronic leg wounds (A Masset)</td>
<td>WS 21: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td></td>
<td>WS G: Early Clot Removal and Stenting in Acute DVT (BOSTON SC.)</td>
<td>WS 22: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td></td>
<td>WS H: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 23: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td></td>
<td>WS I: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 24: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td></td>
<td>WS J: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 25: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td></td>
<td>WS K: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 26: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td></td>
<td>WS L: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 27: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td></td>
<td>WS M: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 28: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td></td>
<td>WS N: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 29: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td></td>
<td>WS O: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 30: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
<td>WS P: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 31: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td></td>
<td>WS Q: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 32: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td></td>
<td>WS R: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 33: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
<td>WS S: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 34: Vascular trauma management (MENTICE)</td>
</tr>
<tr>
<td>17.30-18.00</td>
<td></td>
<td>WS T: Endovascular techniques for chronic lesions of the iliac and femoral veins (BARD)</td>
<td>WS 35: Vascular trauma management (MENTICE)</td>
</tr>
</tbody>
</table>
Spezialkurs Interventionsradiologie zum Erwerb der Fachkunde (§18a RöV)

Anwendung von Röntgenstrahlung bei fluoroskopischen Interventionen an einem Organsystem und Röntgendiagnostik eines Organsystems: Gefäßsystem (peripher/zentral)

Datum: Mittwoch 06.12.2017 (9.00 – 16.30 Uhr)
Veranstalter: Univ.-Prof. Dr. H.-H. Eckstein
Kursleitung/Dozenten: OA Dr. H. Wendorff (Fachkunde Interventionsradiologie)
lt. OA PD Dr. A. Zimmermann (Fachkunde Interventionsradiologie)
Dipl.-Phys. B. Renger (Strahlenphysiker des Instituts für Röntgendiagnostik)
OA Dr. Ch. Maegerlein (Facharzt Radiologie, OA Neuroradiologie)
OA Dr. T. Stadlbauer (Facharzt für Kardiologie)

Ort: Seminarraum M2a, Klinik und Poliklinik für Vaskuläre und Endovaskuläre Chirurgie, Klinikum rechts der Isar, Ismaningerstr. 22, 81675 München.

BLAEK-Punkte/Kategorie: 8 Punkte / Kategorie H
Gebühr: Externe Kollegen: EUR 180, Hausinterne Kollegen: EUR 50
Voraussetzung: Approbation, Grundkurs und Spezialkurs Röntgendiagnostik (nicht älter als 5 Jahre)

Inhalt:
- Physikalisch-technische Grundlagen der Interventionsradiologie (Geräte- und Detektortechnologie - Dosismessgrößen - apparative Einflussfaktoren auf die Dosis - Aufnahmeparameter: Bedeutung für Bildqualität und Strahlenexposition)
- Medizinische Anwendungen der Interventionsradiologie (Dosiswerte bei häufigen Untersuchungen - Strahlenexposition des Patienten und des Personals - Maßnahmen zur Dosisreduktion bei Patienten und Personalspezielle Techniken und ihre Anforderungen im Anwendungsbereich Gefäßinterventionen. Praxisbezogene Übungen und Demonstrationen zu dosisreduzierenden Maßnahmen - Fallbeispiele zur Analyse von Fehlern)

Zielgruppe: Gefäßchirurgen/Gefäßmediziner, die interventionell tätig sind, zur Erlangung der Fachkunde.

Hinweise: Anmeldung erforderlich, Teilnahmebestätigung

Teilnehmerzahl: Dieser Kurs ist auf 20 Teilnehmer begrenzt
CAROTID ISSUES (CAR) - LECTURE HALL B

09.00 - 10.00 CAR 1: Asymptomatic carotid disease – how to select reliably individuals with an increased carotid-related stroke risk
Chair: Hans-Henning Eckstein, Holger Poppert

- A simple long-term stroke risk model for asymptomatic carotid stenosis – will it help us select patients for intervention in the future? - A. Halliday
- Morphological duplex ultrasound criteria - how to assess and report echolucency, inhomogeneity and ulceration - D. Staub
- Plaque area and plaque volume rather than the degree of stenosis are suitable predictors for an increased stroke risk - H. Sillesen
- The risk of MR-detected carotid plaque hemorrhage on recurrent or first-time stroke: a meta-analysis of individual participant data - A. Schindler*
- Keynote lecture: Are Transcranial Doppler (TCD) embolization, impaired cerebrovascular reserve, stenosis progression and silent infarctions suitable tools to select patients for CEA or CAS? - P. Ringleb

10.00 - 11.00 CAR 2: Update on carotid trials and guidelines
Chair: Henrik Sillesen, Werner Hacke

• The most important recommendations from the 2017 ESVS/ESC guideline on the management of carotid artery disease - G. de Borst
• The procedural risk of carotid revascularisation declined over time – data from the Carotid Stenosis Trialists Collaboration - M. Müller*
• The impact of age and sex on stroke and death rates after CEA or CAS – data from the German Carotid Registry - A. Kühnl, S. Schmid
• Restenosis and its impact on recurrent stroke risks after CAS and CEA for symptomatic carotid stenosis – results from the International Carotid Stenting Study - L. Bonati
• Asymptomatic Carotid Endarterectomy Risk Score (ACER score): An individual patient data meta-analysis to identify risk factors for procedural stroke among 6,500 patients undergoing CEA in the VACS, ACAS, ACST-1 and GALA RCTs - R. Bulbulia
• Intraoperative morphological control after CEA - angiography or duplex ultrasound, first results from the CIDAC (Comparison of Intraoperative Duplex Ultrasound and Angiography after Carotid Endarterectomy) trial - C. Knappich

11.30 - 12.40 CAR 3: Emergency treatment of ischemic strokes
Chair: Claus Zimmer, Martin Dichgans

• Keynote Lecture: Mechanical thrombectomy: which results can we expect in clinical routine? Exit light - enter night - W. Hacke
• How to optimize the logistics of endovascular stroke treatment - should the patient come to the doctor or vice versa? - H. Poppert
• Urgent/emergency CEA in stroke patients - L. Capoccia
• Carotid-related strokes with intracranial embolism – endovascular treatment with simultaneous or staged CAS (or CEA) - M. Wildgruber
• Acute carotid artery occlusion – why endovascular intervention is the therapy of first choice - K. Mathias

* Competing for the MAC Award
SPECIAL LECTURE - LECTURE HALL B
12.45 - 13.00  SPECIAL LECTURE: Vascular surgery in the wake of financial crisis - C. Liapis

CAROTID ISSUES (CAR) - LECTURE HALL B
14.00 - 15.10  CAR 4/ PAD 1: Deciphering molecular and cellular mechanisms of atherosclerotic plaque destabilization
Chair: Lars Maegdefessel, Gert de Borst
  • Keynote lecture: Targeting inflammatory processes in atherosclerosis - C. Monaco
  • Rationale for statin use in carotid intervention - periprocedural and long-term effects on plaque stability - S. Macdonald
  • Novel markers and mechanisms of plaque rupture governed by smooth muscle cells - L. Perisic Matic
  • Acute and chronic stress as triggers of plaque vulnerability - H. Sager
  • Preoperative hypertension is associated with atherosclerotic plaque vulnerability in patients undergoing carotid endarterectomy - L. Fassaert*

15.40 - 16.35  CAR 5: Carotid plaque erosion, plaque vulnerability and perspectives in functional imaging
Chair: Peter Ringleb, Eva Bartels
  • Novel insights into atherosclerosis: from pathology to invasive imaging - P. Nicol, M. Joner
  • Use of contrast-enhanced ultrasound for risk stratification of carotid plaques - D. Staub
  • The carotid plaque imaging in acute stroke (CAPIAS) study and the potential role of ipsilateral complicated AHA lesion type VI carotid artery plaques in patients with cryptogenic stroke - M. Dichgans
  • Recent advances in the diagnostics of carotid lesions by MultiSpectral Optoacoustic Tomography (MSOT) - A. Karlas, V. Ntziachristos, M. Kallmayer

**COMPETING FOR THE MAC AWARD**
AORTIC ISSUES (AOR) - LECTURE HALL C

10.30 - 12.40  AOR 1: Short communications I - Aortic diseases
Chair: Stefan Ockert, Marc Bailey, Jürgen Falkensammer, Igor Končar
• The potential benign nature of type Ia endoleaks after fenestrated Anaconda EVAR – truth or myth? - C. Zeebregts
• Mid-term results of 300+ patients treated by endovascular aortic sealing (EVAS) - J. P. de Vries
• How much open surgery is still required for the treatment of AAAs? - R. Kolvenbach
• Direct oral anticoagulants in the treatment of mural thrombus in near-normal aortic wall - T. Soares*
• Retrograde mesenteric bypass case report - A. A. Rahim*
• Visceral branches aneurysm of the abdominal aorta: anatomical layout and choice of treatment - A. Nykonenko*
• Endovascular management of isolated iliac artery aneurysms - single-center experience - M. Generalov*
• Cerebral protection during aortic de-branching with temporary cross-over bypass between external carotid arteries followed by TEVAR – mid-term results - D. M. Oztas*
• Atypical debranching in patients undergoing TEVAR for thoracoabdominal aortic aneurysm type II - P. Nierlich*
• Early experiences with the Relay Double Branch graft - M. Lescan
• Endovascular treatment of hepatic artery pseudoaneurysm after pancreatecoduodenectomy - A. C. Lopes*
• Surgical treatment of the aneurysm of the abdominal aorta after an unsuccessful endovascular treatment in the presence of its quick growth and a nonspecific gastrointestinal bleeding - I. Shevchenko*
• Preoperative pharmacological conditioning affects the clinical and molecular outcome of ischemia / reperfusion injury of the spinal cord after thoracic aortic clamping - a mouse model - F. Simon*
• Novel screening tool for abdominal aortic aneurysms based on Plasma D-Dimer and Myeloperoxidase - W. Eilenberg*
• Management of ruptured abdominal aortic aneurysms (rAAA): 10-year experience at a tertiary referral centre in Northern England - M. A. Waduud*

14.00 - 15.00  AOR 2: Endovascular aortic arch repair - how far can we go?
Chair: Christoph Nienaber, Alexander Zimmermann
• Endo versus open arch repair - what is evidence - what is anecdote? - N. Cheshire
• Total endovascular aortic arch repair in patients who cannot undergo classical surgery - the double endo approach - M. Czerny
• The role of stent grafts in ascending aortic aneurysms - R. Kolvenbach
• Advances and perspectives of arch endografts - S. Haulon
• How to protect the brain during aortic arch endografting? - T. Kölbel
• How to prevent cerebral (micro)embolism during TEVAR of the aortic arch - R. Gibbs

* Competing for the MAC Award
AORTIC ISSUES (AOR) - LECTURE HALL C
15.30 - 17.00
AOR 3: Acute aortic dissections – lessons from the International Registry of Aortic Dissections (IRAD) and other trials
Chair: Jan Brunkwall, Bijan Modarai, Richard Gibbs
• Keynote lecture: Rationale, design, and key findings from the International Registry of Acute Aortic Dissection (IRAD) - S. Trimarchi
• The ongoing discussion about the definition of "complicated" and "uncomplicated" type B aortic dissections – current status - C. Nienaber
• Early outcomes of acute retrograde dissection in the aortic arch and the ascending aorta – data from IRAD - F. Nauta
• Biomarkers and functional imaging in acute aortic dissections – the Liege study on Dissected Aorta (LIDIA) - N. Sakalihasan
• Endovascular treatment of acute type A aortic dissections - the endo Bentall approach - M. Czerny
• Endovascular treatment of aortic dissection - role of debranching procedures - I. Končar
• Will we still need open surgery for acute aortic dissections in 2025? – a cardiovascular surgeon’s perspective - F. Beyersdorf

PERIPHERAL ARTERIAL DISEASE ISSUES (PAD) - LECTURE HALL C
17.00 - 18.10
PAD 2: Short communications II: Peripheral Arterial Diseases (PAD)
Chair: Athanasios Giannoukas, Mihai Ionac, Sigrid Nikol
• Pharmacology for peripheral arterial disease in the Netherlands; patient journey and platelet aggregation inhibitor prescription - A. Brand*
• Tibio-distal vein bypass in critical limb ischemia and its role as a bail-out procedure for failed tibial angioplasty - F. Enzmann*
• A phase III randomized double-blind placebo-controlled study to assess placental PLX-PAD cells in CLI patients that are not eligible for revascularization - S. Nikol
• Endovascular treatment of TASC II C and D Lesions using different strategies - V. Kipiani*
• Late groin complications after cardiac transplantation, repaired by endovascular techniques with unexpected findings in the wound - D. Ruiz Chiriboga*
• The use of bioactive stent heliflex in patients with atherosclerotic lesions of superficial femoral artery: The beginning of the study - M. Generalov*
• The role of transcutaneous oxygen tension measurement in the assessment and classification of lower limb ischemia - B. Leenstra*
• Hyperhomocysteinemia as a marker of cardiovascular disease - I. Pertsov*
• Long-term results of cava filter implantation in the common iliac vein - A. Korotkikh*
• Clinical use and safety of the Lutonix DCB for the treatment of below-the-knee arteries: interim data from a prospective registry - A. Zimmermann
• Endovascular femoro-popliteal bypass grafting via the femoral vein (PQ Bypass) - the DETOUR I study - Y. Bausback
• The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus POBA in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: primary endpoint and 6 months results of a randomized controlled trial - U. Teichgräber

* Competing for the MAC Award
PERIPHERAL ARTERIAL DISEASE ISSUES (PAD) - LECTURE HALL B
08.30 - 09.30

PAD 3: Randomized Controlled Trials (RCT) on Critical Limb Ischemia (CLI) and Intermittent Claudication
Chair: Frank Vermassen, Thomas Zeller
- 1-year results of the RAPID trial – a RCT between Legflow DCB and Supera stent versus Supera stent only - J. P. de Vries
- 2-year result of the REAL PTX randomized trial comparing Silver PTX versus DCB in femoro-popliteal lesions - Y. Bausback, D. Scheinert
- Drug-coated balloons versus uncoated PTA balloons for femoro-popliteal lesions – 12-month results from the randomized RANGER trial - G. Tepe
- Compare I: Pilot Study to compare the Ranger DCB with IN.PACT DCB in patients with femoro-popliteal artery disease - Y. Bausback, D. Scheinert
- First results from the ZILVERPASS Study: a RCT comparing ZILVER PTX stenting with bypass surgery in femoro-popliteal lesions - G. Biro, A. Zimmermann, M. Bosiers
- Stent versus bypass for femoro-popliteal TASC II Type C and D lesions: preliminary data of a prospective randomized trial - F. Enzmann
- Endovascular atherectomy versus open femoral endarterectomy – rationale and design of the randomized PESTO Trial - T. Zeller

09.30 - 10.35

PAD 4: Update on atherectomy and drug-eluting technologies
Chair: Klaus Overbeck, Heiko Wendorff
- Open surgery or stenting for aortoiliac occlusive disease - which is best? - R. Gibbs
- Technique and outcomes of Laser-Atherectomy for calcified femoro-popliteal lesions - R. Ghotbi
- Update on drug-eluting balloons (DEB) – are they all the same? - F. Vermassen
- BIOULTX 4EVER and IN.PACT Flexion: physician-initiated studies on DCB and bare metal stents in femoro-popliteal and popliteal lesions - M. Bosiers
- Unmet need in SFA treatment: severe calcium - what the „shockwave (lithotrypsy)” device might add (data of the PAD II study) - G. Tepe
- Keynote Lecture: Technological perspectives for endovascular therapy of the lower limb - T. Zeller

11.00 - 12.15

PAD 5: PAD - a marker disease for atherosclerosis – update on antithrombotic and lipid-lowering therapy
Chair: Heribert Schunkert, Christos Liapis
- Keynote lecture: Population screening and intervention for vascular disease in Danish men (VIVA): a randomized controlled trial - J. Lindholt
- The secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Rivaroxaban - C. Espinola-Klein
- Is the combination of antithrombotics and low-dose anticoagulants worthwhile in PAD – the VOYAGER trial - T. Stadlbauer
- Cholesterol: The good, the bad and the ugly! Results of recent HDL-C raising trials to prevent vascular disease - R. Bulbulia
- The impact of Evolocumab (PCSK 9i) on clinical outcomes in patients with cardiovascular disease – the randomized FOURIER study - H. Schunkert
- Key recommendations on antithrombotic and lipid-lowering therapy from the 2017 guidelines of the European Society for Cardiology - C. Espinola-Klein

SPECIAL LECTURE - LECTURE HALL B
12.15 - 12.30

SPECIAL LECTURE: The “vasculo-plastic” approach to reduce the number of lower limb amputations due to chronic tissue loss - M. Ionac

PERIPHERAL ARTERIAL DISEASE ISSUES (PAD) - LECTURE HALL B
13.30 - 14.45

PAD 6: New assessment tools for Critical Limb Ischemia (CLI)
Chair: NN, Ulf Teichgräber
- Angiosomes - a failed concept? - F. Vermassen
- Novel assessment of haemodynamics (pressure, flow, fractional flow reserve) in the peripheral vasculature using the Combowire B. Modarai
- DETECT-PAD - a computerized model to predict the pressure drop in borderline iliac artery stenosis on the basis of MRA - J. P. de Vries

* Competing for the MAC Award
• Lesions in the superficial femoral artery (SFA) characterized with velocity ratios using vector velocity ultrasound – L. Lönn
• Endovascular treatment of aorto-iliac TASC D occlusions with fusion imaging, outback catheters, dedicated wires and stent grafts – K. Overbeck
• Arm veins are a reliable and durable graft material in femoro-popliteal and distal bypass surgery - A. Neufang

14.45 - 15.40 PAD 7: Acute Limb Ischemia (ALI) - open or endovascular treatment?
Chair: Thomas Schmitz-Rixen, Markus Steinbauer
• The ROBINSON study: a physician-initiated study investigating the Rotarex Catheter in femoro-popliteal in-stent occlusions - M. Bosiers
• Plasma fibrinogen level as predictor of hemorrhagic complications after catheter directed thrombolysis - G. de Borst
• Percutaneous thrombectomy for acute limb ischemia - equipment, technique and results - A. Katsargyris
• Endovascular treatment of ALI is better than open surgery; results from a nationwide study with long-term follow-up - M. Björck
• How previous revascularizations affect the outcomes of acute limb ischemia – a consecutive cohort of 200 patients - K. Stoklasa

CAR / PAD / AOR - LECTURE HALL B
16.10 - 17.55 CAR 7/PAD 8/AOR 9: Radiation protection and team training 2017
Chair: Moritz Wildgruber, NN
• Keynote lecture: Determinants of occupational radiation exposure and current practice of radiation protection in the Hybrid OR - B. Modarai
• Radiation exposure during venous stenting - H. Jalaie
• Key points in radiation protection in the angio lab – experiences and advices from an endovascular pioneer - K. Mathias

AORTIC ISSUES (AOR) - LECTURE HALL C
08.30 - 09.30 AOR 4: Cutting-edge imaging technologies for the aorta
Chair: Nick Cheshire, Natzi Sakalihasan
• Use of Fusion imaging in fenestrated and branched EVAR - does it work? - A. Katsargyris
• Perspectives of Magnetic Resonance Imaging (MRI) for aortic aneurysms and dissections - J. Nadjiiri
• What Spectral CT Angiography could add in the (follow-up) diagnostics of aortic diseases - M. Rasper
• Apposition software to calculate apposition of endografts in the aortic neck – prediction of EVAR failures during follow-up - J. P. de Vries
• Molecular imaging of cell proliferation in pre-clinical abdominal aortic aneurysm - M. Bailey

09.30 - 10.45 AOR 5: Novel concepts and insights from translational aortic aneurysm research
Chair: Philip Tsao, Lars Maegdefessel
• Keynote Lecture: Pathophysiological impact of diabetes on AAA disease - R. Dalman
• Molecular and cellular mechanisms of thoracic aortic aneurysms - P. Eriksson
• Cancer and AAA: a causal role for chronic inflammation? - N. Sakalihasan
• Physical activity and the risk to develop AAA - M. Björck
* Competing for the MAC Award
• Ticagrelor and the inhibition of growth in small AAAs – results from a RCT - A. Wanhainen
• Skin accumulation of advanced glycation endproducts is increased in AAA patients - C. Zeebregts

AORTIC ISSUES (AOR) - LECTURE HALL C
11.10 - 12.30
AOR 6: Chronic aortic dissections and thoraco-abdominal aortic aneurysms – technical issues and long-term outcomes
Chair: Tina Cohnert, Piotr Kasprzak, Friedhelm Beyersdorf
• Perioperative mortality, paraplegia, stroke and long-term stent related complications after TEVAR for traumatic thoracic aortic lesions - C. Zeebregts
• A dissection-specific stent graft to prevent distal Stent-graft induced New Entry (dSINE) - A. Wanhainen
• Mechanisms of and treatment strategies for dSINE after TEVAR for acute and chronic type B aortic dissection- Insights from EuREC - M. Czerny
• False lumen embolisation: devices and techniques. - T. Kölbl
• Are all thoracic endografts the same? - N. Chakfé
• The compliance with “best” medical therapy in type B aortic dissection patients is poor – we need to optimize medical treatments to improve long-term outcomes - C. Bicknell
• Update on long-term durability of fenestrated and branched endografts for Thoraco-Abdominal Aortic Aneurysms (TAAA) - A. Katsargyris

13.30 - 15.10
AOR 7: Abdominal aortic aneurysms (AAA) – genetics, guidelines and outcomes after open and endovascular repair
Chair: Anders Wanhainen, Jes Sanddal Lindholt
• Keynote lecture: Genetics of AAA – what clinicians need to know in 2017 - P. Tsao
• Update on the 2017 AAA management guidelines of the Society of Vascular Surgery (SVS) - R. Dalman
• The 5.5 cm/5 cm threshold is completely arbitrary, some AAAs rupture at smaller diameters - F. Vermassen
• Determinants of survival after EVAR - an analysis of >700 endovascular aortic procedures to determine 5-year survival - B. Modarai

15.40 - 16.40
AOR 8: Endoleaks type I and III – still an unresolved issue in endovascular repair of juxtarenal AAA and TAAA
Chair: Ron Dalman, Hubert Schelzig
• How I plan and perform fenestrated aortic endografting and how I flare the viscero-renal grafts to prevent type III endoleaks - S. Haulon
• Routine closure of gutters with liquid polymer solves the chimney problem and makes them as good as fenestrated grafts - R. Kolvenbach
• Viscero-renal stent graft for chimneys, FEVAR and BEVAR – which one is better or are they all the same? - A. Assadian
• Patient selection in hostile necks and how to prevent endoleaks – a word of caution - P. Kasprzak
• The role of parallel grafts and endovascular aortic sealing (EVAS) - do they fill a gap? - I. Loftus
• Benchside testing for patient safety: assessment of pull-out forces before complex EVAR - J. Falkensammer

* Competing for the MAC Award
CAROTID ISSUES (CAR) - LECTURE HALL C

16.45 - 18.15  CAR 8: Short communications III: Carotid stenosis (CAR)
Chair: Richard Bulbulia, Kornelia Kreiser, Daniel Staub

• Carotid endarterectomy and carotid stenting in patients with atrial fibrillation with using Dabigatran Etxelilate - A. Korotkikh*
• Smoking is a significant risk-factor for postoperative cerebral events in CABG and simultaneous internal carotid endarterectomy - P. Konstantiniuk*
• Clinical and cytological correlation in the vulnerable atherosclerostic carotid plaque: monocentric experience - A. Carmignani*
• Smooth muscle cells’ level of MMP-9 and TIMP-1 could potentially indicate plaque instability - G. Voulalas*
• Case of successful combined treatment of giant paraganglioma of neck - I. Shevchenko*
• How to clamp and revascularize the brain if the patient has only single vessel blood supply that contains severe stenosis? - D. M. Oztas*
• CEA for patients with a recurrent symptomatic internal carotid artery near occlusion with full collapse: report of 17 cases - A. Meershoek*
• Repeated carotid endarterectomy: Do plaques change over time? - I. D. van Koeverden*
• A long-term observational study of carotid artery treatment - K. Spanos*
• Perioperative platelet inhibition is a MUST - data from the German Carotid Registry on 117,973 procedures - A. Zimmermann
• Transcarotid Artery Stenting (T-CAR) with flow reversal – our experience with this innovative tool to treat carotid stenoses - M. Kallmayer
• Innervation of extracranial carotid aneurysms and popliteal aneurysms - V. Pourier*
• The assessment of carotid stenoses by contrast-enhanced tomographic ultrasound - C. Schäffer
• Significant association between the neurological status on admission and the in-hospital risk of stroke or death after CEA and CAS - A. Kühnl

* Competing for the MAC Award
VENOUS SYMPOSIUM (VEN) - LECTURE HALL B

09.00 - 10.20 VEN 1: Endovenous therapy or open surgery for primary varicosis - what is the evidence?
Chair: Ingo Flessenkämper, Richard Brandl

- Long-term results of surgical and endovenous procedures for primary varicosis - an analysis of the past RCTs - A. Mumme
- What can we learn from randomized trials comparing endovenous and open surgery for primary varicosis? – an overview - T. Pröbstle
- Is there any evidence that endovenous laser therapy or radiofrequency ablation or foam sclerotherapy is superior to each other? - C.-G. Schmedt
- Impact of inguinal varicose veins recurrence and modern therapeutic strategies - D. Tsantilas
- Keynote lecture: New insights into the genetics of primary varicosis - A. Fiebig

10.20 - 11.15 VEN 2: Update on new endovenous technologies for primary varicosis
Chair: Achim Mumme, Claus-Georg Schmedt

- The European Sapheon™ Closure System ObservatioNetive (eSCOPE) Study – clinical results and side effects of Venaseal - T. Pröbstle
- Non-thermal / non-tumescent (NTNT) ablation of the truncal veins – indications and limitations - T. Hirsch
- The introduction of glue in my venous armamentarium – 3-year results - R. Brandl
- Steam Vein Sclerosis – an alternative to mini-phlebectomy? - F. Netzer

11.45 - 12.55 VEN 3: Prevention and medical therapy of deep vein thrombosis (DVT)
Chair: Christine Espinola-Klein, Sebastian Schellong

- Keynote lecture: Oral anticoagulation and DVT: what is the evidence and is there a need to anticoagulate every lower leg DVT? - S. Schellong
- Reduced-dosed Rivaroxaban in the long-term prevention of recurrent symptomatic DVT – the Einstein-Choice trial - T. Stadlbauer
- DVT as the first sign of an occult malignant disease- how often and what is the adequate diagnostic approach? - S. Schreiber
- Update on the risk of DVT during air travel - does the economy class syndrome really exist? - T. Stadlbauer

12.55 - 13.55 VEN 4: Recanalization strategies in acute and chronic deep venous thrombosis
Chair: Ingo Flessenkämper, Tobias Hirsch

- What do we learn from the RCTs regarding venous recanalisation? How to design a trial which really moves the field forward? - S. Schellong
- What does it need to perform endovenous recanalization in acute and chronic occlusions successfully - lessons learned - H. Jalaie
- Acute venous iliofemoral thrombosis: early surgical thrombectomy is effective and durable - S. Ockert
- Phlegmasia coerulea dolens – diagnostics and management - A. Mumme

VENOUS SYMPOSIUM (VEN) - LECTURE HALL B
MINI-SYMPOSIA | THURSDAY, DECEMBER 07, 2017

MINI-SYMPOSIUM 1 - CONFERENCE ROOM 1
17.00 - 18.10 Mini-Symposium I: Aortic infections
Chair: Christian Reeps, Martin Björck

• Inflammatory AAA and postoperative outcomes after open-surgery: a 10-year single-center experience and state of the art - H. Schelzig
• EndoVAC hybrid treatment of vascular infection - A. Wanhainen
• The contemporary management of infected aortic grafts: endovascular stenting saves lives but definitive surgery is necessary - C. Bicknell
• Treatment of graft infections after open and endovascular aortic treatment by orthotopic reconstruction with bovine neopericardium from the root to the bifurcation - M. Czerny
• The European multicenter registry on pericardial grafts for aortic infections - T. Wyss
• How to design tube and bifurcated pericardial grafts (technical note) - G. Biro
• Deep vein remains to be a valid alternative for orthotope aortic repair - C. Reeps

MINI-SYMPOSIA | FRIDAY, DECEMBER 08, 2017

MINI-SYMPOSIUM 2 - CONFERENCE ROOM 1
15.30 - 16.30 Mini-Symposium II: Vertebrobasilar strokes and carotid artery pseudoocclusion
Chair: Holger Poppert, NN

• Open surgical options to treat extracranial vertebral lesions - A. Assadian
• Advances in the treatment of posterior cerebral circulation symptomatic disease - A. Giannoukas
• Treatment of supra-aortic trunks occlusive disease - N. Chakfé
• The vertebral artery – a forgotten vessel? - K. Mathias
• Management of patients with internal carotid artery near-total occlusion - C. Liapis

The Clear DCB Choice
Built on a Clinically Proven SFA Coating Technology.
AVAILABLE FOR ATK .035” AND BTK .014”
<table>
<thead>
<tr>
<th>No.</th>
<th>TIME</th>
<th>TOPICS</th>
<th>SPONSOR</th>
<th>CONVENOR</th>
<th>ROOM</th>
</tr>
</thead>
</table>
| WS-1  | 9.30-11.00 | Atherectomy for calcified peripheral lesions – indications and techniques  
• Indications  
• Procedural aspects  
• Limitations | SPECTRANETICS | Reza Ghotbi, Munich, Germany | Conference room 1 |
| WS-2  | 9.30-11.00 | Technical tips, tricks, and pitfalls for the new Zenith Alpha Abdominal EVAR device - when is it the best option for treating an AAA? | COOK         | Alexander Zimmermann, Munich, Germany         | Lecture Hall Pavillon |
| WS-4  | 11.00-12.30 | Suture mediated LH preclosing technique / Proglide - percutaneous closing device  
• Data and indications  
• Technique and applications  
• Hands-on training on simulators  
• Troubleshooting | ABBOTT       | Alexander Zimmermann, Munich, Germany and Daniel Markert, Germany | Lecture Hall Pavillon |
| WS-3  | 11.30-13.00 | How to perform in-situ-bypass surgery in critical limb ischemia  
• Indications  
• How to deal with side branches  
• How to perform valvulotomy safely  
(This workshop will be held in German.) | LE MAITRE    | Mario Kuhnert, Birkenwerder, Germany and Udo Warkotsch Offenbach, Germany | Seminar room M2a |
| WS-6  | 13.00-14.30 | Endovascular options for type B aortic dissections  
• Therapeutic options  
• Outcomes after conservative and endovascular treatment  
• Individualized planning of TEVAR | VASCUTEK     | Mario Lescan, Tübingen, Germany | Lecture Hall Pavillon |
| WS-5  | 14.00-15.30 | DAART: Directional atherectomy and antirenostotic therapy  
• Hand’s on training „Hawk One“ and „Spider FX“ embolic protection device  
• Indications Hawk One 6 and 7 French  
• Case examples SFA and BTK | MEDTRONIC    | Martina Lopatta, Munich, Germany and Sven Wick, Munich, Germany | Conference room 1 |
| WS-8  | 14.30-15.30 | Education and training in major amputation techniques in vascular surgery  
• Optimal levels of amputation  
• When is a primary amputation reasonable  
• When to perform a forefoot amputation primarily | no sponsor   | Markus Steinbauer, Regensburg, Germany | Lecture Hall Pavillon |
| WS-A  | 16.00-17.00 | The management of ruptured AAA - how I do it  
• rAAA algorithm  
• Aneurysm morphology  
• Team approach | no sponsor   | Thomas Wyss, Berne, Switzerland | Conference room 1 |
| WS-7/1| 17.00-18.00 | Flaring of the Bentley BeGraft during fenestrated EVAR  
The objective is to learn how to do the correct deployment and flaring of the BeGraft when used in fenestrated grafts. This is demonstrated in a simulator for hands on training. | BENTLEY      | Stephan Haulon, Paris, France | Lecture Hall Pavillon |
<table>
<thead>
<tr>
<th>No.</th>
<th>TIME</th>
<th>TOPICS</th>
<th>SPONSOR</th>
<th>CONVENOR</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>WS-C</td>
<td>09.00-10.30</td>
<td>Cruro-pedal bypass surgery – indications and techniques</td>
<td>no sponsor</td>
<td>Achim Neufang, Wiesbaden, Germany</td>
<td>Conference room 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• How to diagnose a patent distal artery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• How to get there easily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Choice of the bypass material</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Completion studies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS-8</td>
<td>09.00-10.30</td>
<td>Acute ischemic stroke management. A procter led simulator workshop with a focus on procedural technique and radiation safety</td>
<td>MENTICE</td>
<td>Kornelia Kreiser, Munich, Germany and Lars Lönn, Copenhagen, Denmark</td>
<td>Lecture Hall Pavillon</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Case scenarios</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Team training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Cerebral intervention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS-13</td>
<td>10.00-13.00</td>
<td>EVAR workflow from sizing to stent deployment</td>
<td>SIEMENS/VASCUTEK</td>
<td>Verena Kneissl and Dirk Sunderbrink, Erlangen, Germany</td>
<td>Seminar room M2a</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Image guidance in vascular surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Anaconda™ – Indications and possibilities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Treo® – Indications and possibilities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Demo: Cios Alpha</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Hands on: Implantation of anaconda™ and Treo® Endovascular Devices in a model in the OR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS-D</td>
<td>10.30-11.30</td>
<td>How to create an endovascular team (doctors, nurses, technicians) for Hybrid Operating Rooms</td>
<td>no sponsor</td>
<td>Johannes Gahlen, Ludwigsburg, Germany</td>
<td>Lecture Hall Pavillon</td>
</tr>
<tr>
<td>WS-9</td>
<td>11.00-12.30</td>
<td>MENTICE hands-on simulator training on Vascular Trauma Management</td>
<td>MENTICE</td>
<td>Lars Lönn, Copenhagen, Denmark</td>
<td>Conference room 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Endovascular Aortic Repair (EVAR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pelvic trauma management with embolisation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Iliac/SFA interventions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS-E</td>
<td>11.30-12.30</td>
<td>Experimental vascular models and vascular biobanking</td>
<td>no sponsor</td>
<td>Lars Maegdefessel, Munich, Germany</td>
<td>Lecture Hall Pavillon</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Implementation of a vascular laboratory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Which animal models are available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Logistics of a vascular biobank</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>TIME</td>
<td>TOPICS</td>
<td>SPONSOR</td>
<td>CONVENOR</td>
<td>ROOM</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------------</td>
<td>--------------------</td>
</tr>
</tbody>
</table>
| WS-10 | 13.30-15.00 | Endovascular techniques for chronic lesions of the iliac and femoral veins  
  • Patient recruitment  
  • Diagnostic  
  • Correct indication  
  • Technique  
  • Tips and tricks  
  • Equipment  
  • Management of complication | C.R. BARD GMBH               | Houman Jalaie, Aachen, Germany | Conference room 1               |
| WS-11 | 13.30-15.00 | Carotid endarterectomy (CEA) with bovine pericardial patching  
  • Carotid Endarterectomy (CEA) on lifelike models  
  • How to handle pericard patches  
  • Intraluminal shunting with the Pruitt Shunt  
  *(This workshop will be held in German)* | LE MAITRE                    | Mario Kuhnert, Birkenwerder, Germany  
  and Udo Warkotsch, Offenbach, Germany | Lecture Hall Pavillon        |
| WS-F  | 15.30-16.30 | Modern concepts in the therapy of chronic leg wounds                   | no sponsor                     | Andrea Masset, Munich, Germany     | Lecture Hall Pavillon |
| WS-12 | 16.30-18.00 | Early Clot Removal and Stenting in Acute DVT                           | BOSTON SCIENTIFIC              | Torsten Fuß, Radebeul, Germany     | Conference room 1    |
| WS-7/2| 16.30-17.30 | Flaring of the Bentley BeGraft during fenestrated EVAR                 | BENTLEY                        | Stephan Haulon, Paris, France      | Lecture Hall Pavillon |
Proven design.

From the proximal to the distal seal, the Zenith Alpha™ Abdominal device is engineered to help you deliver a durable repair.

Zenith Alpha™
ABDOMINAL ENDOVASCULAR GRAFT

≥15 MM SEAL ZONE
3 PIECE MODULAR SYSTEM
DURABLE REPAIR

Learn more at cookmedical.eu/aortic-intervention.

Some products or part numbers may not be available in all markets. Contact your local Cook representative or Customer Service for details.

Note: Grafts shown in anatomy are:
Zenith Alpha™ Abdominal Endovascular Graft
Zenith Alpha Spiral™ Endovascular Leg
Zenith® Branch Endovascular Graft—Blal Bifurcation

Indications, operating specifications and availability may vary by country. Check with local product representation and country-specific Information for use for your country. This material is not approved for use or distribution in France.

© COOK 2017 A453522.ENLT

www.bostonscientific.eu
KEYNOTE LECTURE

Are Transcranial Doppler (TCD) embolization, impaired cerebrovascular reserve, stenosis progression and silent infarctions suitable tools to select patients for CEA or CAS?

Peter Ringleb, Heidelberg, Germany

Thursday, December 07, 2017 | 09:00-10:00 | CAR 1 | LECTURE HALL B

Prof. Dr. med. Dipl. Inf. (FH) Peter Arthur Ringleb obtained his doctoral degree in 1994 after graduating his parallel studies in computer sciences and medicine in Giessen, Germany. Since 2014, he is Professor for Vascular Neurology and Head of the Neurovascular Service of the University Hospital Heidelberg. His research activities include acute stroke treatment, ultrasound in stroke as well as long-term effect of stentprotected carotid artery and intracranial stenting. Beyond several high-ranking publications, Prof. Ringleb is involved in numerous clinical trials as either Principal Investigator, steering committee member or national coordinator. Within the last 9 years he held several offices: member of the German guideline “Treatment of carotid artery stenosis”, associate editor for Stroke, secretary and member of the managing board of the German Stroke Society, editor for “Gefaesschirurgie”, member of the steering committee of the German guideline “Acute Stroke Treatment”, and Associate Editor for the European Journal of Stroke.

KEYNOTE LECTURE

Mechanical thrombectomy: which results can we expect in clinical routine? Exit light – enter night

Werner Hacke, Heidelberg, Germany

Thursday, December 07, 2017 | 11:30-12:40 | CAR 3 | LECTURE HALL B

Werner Hacke was Professor and Chairman of the Department of Neurology at the University of Heidelberg in Germany from 1987 until 2014 and is now a Senior Professor of Neurology at the Ruprecht Karls University in Heidelberg, Germany. His main scientific and clinical interest is in acute stroke, critical care neurology and in stroke prevention. He has pioneered the field of thrombolysis for acute stroke and initiated several new management options for large infarctions including hypothermia and decompressive surgery.

He was the founding President (now honorary President) of the European Stroke Organization. He is a Past President of the German Neurological Society, the German Stroke Society and the German Interdisciplinary Society of Intensive Care Medicine. He is currently the President of the World Stroke Organization (WSO).

In 1998, he was the first European recipient of the Feinberg Award for Excellence in Stroke Research, and the first recipient of the Karolinska Stroke Award in 2004. He was awarded the Nonne-Medal in 2008, received the Presidents Award by the World Stroke Organisation (2008), the Mihara Award by the Mihara Foundation (Japan, 2009), the Jarecki Award (USA, 2009) and the Wepfer Award of the ESC in 2013. Prof Hacke is honorary member of numerous neurological and neuroradiological Societies. He also holds several honorary doctorates abroad and an honorary professorship by the Universidades dos Andes Santiago de Chile. He was chair of the steering committees of several acute treatment and secondary prevention trials.

Prof. Hacke has published >500 original articles listed in pubmed and SCI. He is the scientist with the highest citation rate worldwide (>50,000) in the field of Stroke and Vascular Neurology (h-index 103 (Web of Science) resp. 124 (Google Scholar)).

KEYNOTE LECTURE

Vascular surgery in the wake of financial crisis

Christos Liapis, Athens, Greece

Thursday, December 07, 2017 | 12.45-13.00 | LECTURE HALL B

Prof. (Em) Christos D. Liapis graduated from the Medical School of the National & Kapodistrian University of Athens, where he also completed his General Surgery residency. He then moved to the States for a three-year clinical fellowship in Vascular Surgery at Ohio State University followed by a year of cardiovascular research at Harvard and the MGH. He returned to Greece and to NKUA where he was elected as Professor of Vascular Surgery and Chairman of the Department of Vascular Surgery that he founded. In 1999, he was elected as Secretary of the UEMS, Division and in 2004 Section of Vascular Surgery and in 2005 President of the ESVS. From 2012-2014 he served as President of the ISVS. He is Honorary Member of many Scientific Societies including the SVS. He is currently the Director of Vascular & Endovascular Clinic at Athens Medical Center and Researcher at the Biomedical Research Foundation of the Academy of Athens. He is Co-Editor of two textbooks, author of more than 37 book chapters and over 320 scientific publications with more than 14,000 citations. His particular areas of research are carotid vulnerability, aortic pathophysiology and experimental atherosclerosis.
KEYNOTE LECTURE
Targeting inflammatory processes in atherosclerosis
Claudia Monaco, Oxford, UK
Thursday, December 07, 2017 | 14.00-15.10 | CAR 4 | LECTURE HALL B

Claudia Monaco is Professor of Cardiovascular Inflammation at the Kennedy Institute of Rheumatology and an Honorary Consultant Cardiologist at the University of Oxford NHS Trust with a special interest in Echocardiography. She also heads the Mass Cytometry Facility at NDORMS. She trained as a Cardiologist (1998) and PhD (2001) at the Catholic University of Rome, Italy. She was privileged to get involved in the field of inflammation in atherosclerosis when it was still in its infancy with the identification of a cytokine-dependent systemic inflammatory response in patients with acute coronary syndromes. Her group was the first to establish innovative experimental methodology for the isolation, culture and pharmacological targeting of live cells from human atheroma lesions. Her Cardiovascular Inflammation Team is focused in dissecting the functions of pattern recognition receptors and their downstream signaling in the vasculature in health and disease. She won several prizes and awards including a Marie Curie EU Fellowship, the Young Investigator Award of the International Society of Thrombosis (1997) and the First Prize of the Young Investigator Award of the European Society of Cardiology (ESC) in the category Thrombosis (2002), and the Oxford-Harrington Scholarship (2015). She is a Fellow of the European Society of Cardiology since 2007. Her lab has been funded over the years by several EU and BHF grants.

KEYNOTE LECTURE
Rationale, design, and key findings from the International Registry of Acute Aortic Dissection (IRAD)
Santi Trimarchi, San Donato Milanese, Italy
Thursday, December 07, 2017 | 15.30-17.00 | AOR 3 | LECTURE HALL C

Santi Trimarchi is associated Professor of Vascular Surgery and Director of Vascular Surgery Residency Program at the University of Milan. He is Head of the section Vascular Surgery II, Director of the Thoracic Aorta Research Center at Policlinico San Donato Research Hospital, as well as Co-director of the Beta Lab – Biomechanics for Endovascular Treatment of the Aorta. He serves as co-investigator and investigator in several international registries and trials. In addition, he is promoter and supervisor of a PhD program on aortic diseases, in collaboration with Utrecht University, the Netherlands, and the University of Michigan, Ann Arbor, USA.

KEYNOTE LECTURE
Pathophysiological impact of diabetes on AAA disease
Ronald Dalman, Stanford, USA
Friday, December 08, 2017 | 09.30-10.45 | AOR 5 | LECTURE HALL C

Stanford Vascular Surgery has grown to become one of the largest academic vascular programs in the USA, with 18 full time vascular surgeons, vascular internists, and biomedical engineers working in 7 different hospitals and health care facilities in Northern California. The program trains 11 residents and fellows, finishing 3 graduates annually. In addition to leading Vascular Surgery, Dr. Dalman Co-Directs the Cardiovascular Service Line and Cardiovascular Research Institute (CVI) at Stanford. Having served as Principal Investigator on multiple NIH grants, Dalman currently directs the CVI NIH T32 training grant entitled “Mechanisms and Innovation in Vascular Disease”. Beyond Stanford, Dalman has served on the Residency Review Committee for Surgery of the Accreditation Council for Graduate Medical Education (USA), on the Vascular Surgery Board of the American Board of Surgery, on the Executive Committee of the Association of Program Directors in Vascular Surgery, as Program Chairman for the Society for Vascular Surgery Vascular Annual Meeting, and as President of the Western Vascular Society.

SPECIAL LECTURE
The “vasculo-plastic” approach to reduce the number of lower limb amputations due to chronic tissue loss
Mihai Ionac, Timisoara, Romania
Friday, December 08, 2017 | 12.15-12.30 | LECTURE HALL B

Mihai Ionac is professor of surgery at the Victor Babes University of Medicine and Pharmacy from Timisoara and Head of the Clinic for Vascular Surgery and Reconstructive Microsurgery. He is board certified in vascular and plastic surgery and he formed a multidisciplinary team integrating vascular (both open and endovascular) and plastic surgery techniques for the salvaging of lower limbs with ischemic tissue loss and for the management of the DFU. Dr. Ionac founded 1994 the Pius Branzeu Center, an experimental facility for training in microsurgery, flap surgery and vascular surgery (www.pius-branzeu-center). Following a training period in Germany he started 1998 an international training program in microsurgery and flap surgery on living tissue, that has been visited by more than 1,000 surgeons from all over the world and is integrated in the European School of Reconstructive Microsurgery (www.rmes.es). Dr. Ionac was President of the Romanian Society for Vascular Surgery (currently serves as secretary general) and is Chairman of the Committee of Registry of UEMS Section and Board of Vascular Surgery.
Determinants of occupational radiation exposure and current practice of radiation protection in the Hybrid OR

Bijan Modarai, London, UK
Friday, December 08, 2017 | 16.10-17.55 | CAR7 / PAD8 / AOR9 | LECTURE HALL B

Bijan Modarai qualified in medicine from Guy’s and St Thomas’ Hospital in 1998 and obtained a PhD in 2006. He completed his vascular surgical training in London and as a visiting Fellow at The Royal Prince Alfred Hospital in Sydney. He was appointed as a Senior Lecturer and Consultant Vascular Surgeon at Guy’s and St Thomas’ Hospitals in 2012. Since then he has led a translational programme of vascular research, producing over 50 high impact publications with several national/international prizes awarded to his research team. He was made Reader in Vascular Surgery in 2015 and appointed as a Hunterian Professor by The Royal College of Surgeons of England in 2016. He was awarded a Senior Fellowship by the British Heart Foundation in 2017.

His clinical practice is focused on complex endovascular aortic repair which also involves research into radioprotection and the effects of radiation exposure during endovascular interventions. Mr Modarai is Programme Chair for the British Society for Endovascular Therapy and examines for the Fellowship of European Board of Vascular Surgery.

Technological perspectives for endovascular therapy of the lower limb

Dr. Thomas Zeller is an Associate Professor in the Angiology Division of the University of Freiburg-Bad Krozingen. He performs interventional angiography with more than 20 years of experience in this field. His main research interest is diagnostic and therapy of renal artery stenosis, optimization of endovascular therapy methods of peripheral arterial occlusive disease and optimization of non-invasive diagnostic methods in vascular medicine. He has performed a series of studies in these areas and has conducted numerous clinical trials. Furthermore, he is editor-in-chief of various scientific journals, e.g., VASA, EUROIntervention, Vascular Medicine, Catheterization Cardiovascular Interventions, Journal of Endovascular Therapy, and Gefaessmedizin.net. He is the author of more than 200 peer reviewed original and review articles, editor of the textbook Vascular Medicine – Therapy and Practice as well as reviewer for European Heart Journal, Journal of American College of Cardiology and sub-journals, Circulation and sub-journals, The Lancet and others.

Populatio screening and intervention for vascular disease in Danish men (VIVA): a randomized controlled trial

Jes Sanddal Lindholt, Odense, Denmark
Friday, December 08, 2017 | 11.00-12.15 | PAD 5 | LECTURE HALL B

Prof. Lindholt graduated medical school in 1990 at Aarhus University, Denmark. He obtained a PhD in 1998 and his doctoral degree in medical sciences (DMSci) in 2010. He completed his residency training in vascular surgery at Aarhus University Hospital (Skejby), Viborg Hospital, and Rigshospitalet, Copenhagen. Currently, Prof. Lindholt is Head of the Cardiovascular Centre of Excellence in Southern Denmark (CAVAC), Professor of Vascular Surgery at Odense University Hospital, and adjunct Professor in Vascular Epidemiology at Viborg Hospital, Aarhus University. He was Principal Investigator of the Viborg study (1994-2009), one of the four RCTs providing the evidence for population based screening for abdominal aortic aneurysms. Later as part of the European Research Consortium “Fighting Aneurysmal Disease (FAD)”, he served as Principal Investigator of the VIVA trial 2008 – examining the benefits and harms regarding triple vascular screening for AAA, PAD and hypertension. Prof. Lindholt co-founded the Elitary Research Centre for Individualized Medicine...
KEYNOTE LECTURE
New insights into the genetics of primary varicosis
Andreas Fiebig, Kiel, Germany
Saturday, December 09, 2017 | 09.00-10.20 | VEN 1 | LECTURE HALL B

Andreas Fiebig obtained his PhD in Biochemistry and Biotechnology at the University of Münster/Germany (see publication in the Journal of Biochemistry in 2005). From 2005 onwards, he was privileged to get involved in the field of high throughput genetics at the Institute of Molecular Genetics in Kiel/Germany. He was the first to establish the genetic background of Chronic Venous Diseases (Heritability of chronic venous disease, Hum Genetic, 2009). In 2017, as part of a large German research group, he identified the first three risk loci for CVD in a GWAS attempt (Sci. Rep. 2017 Apr 4;7:45652).

As managing director of the competence network of chronic venous diseases (Kiel, Berlin), he is involved in various scientific and technical research projects since 2009. Andreas Fiebig also participates in international cooperation projects being project manager as well as speaker of the initiative of competence networks in Life Sciences. From 2015 to 2017 he was director of the Initiative of competence networks in Life Sciences (Kiel, Berlin, Frankfurt) interacting with international research centers. Since 2017 he is senior director of the Initiative of competence networks in Life Sciences. As managing director of the corresponding operative platform (InterMedCon, since 2016) he will continue the international cooperation with Japan and the Netherlands including INTERREG-Programme MIND (“Medical Innovation Germany Netherland”, Münster, EU).

Specific research interests include (1) mechanisms regulating chronic venous diseases, (2) role of neoangiogenesis, (3) genomic and transcriptomic discovery in human chronic venous diseases disease, and (4) biomarker identification (including genetic) for risk prediction. Technical interests are full automated storage systems, new GWAS approaches, humanoid robotics, tracker technology for cardiovascular diseases and care management concepts.

KEYNOTE LECTURE
Oral anticoagulation and DVT: what is the evidence and is there a need to anticoagulate every lower leg DVT?
Sebastian Schellong, Dresden, Germany
Saturday, December 09, 2017 | 11.45-12.55 | VEN 3 | LECTURE HALL B

Sebastian Schellong graduated from the University of Lübeck in Germany, in 1984. After completing his residency in internal medicine at Hannover Medical School, Professor Schellong served as the Head of the Division of Angiology in the Clinic for Cardiology Angiology and Pneumonology, at the Otto-von-Guericke-University in Magdeburg in Germany.

Since 1995, he has been Head of the Division of Angiology, faculty of medicine ‘Carl-Gustav-Carus’ at the Technical University in Dresden. In 1997 he was appointed as university lecturer for Internal Medicine at the Technical University, and was appointed as director of the University Center for Vascular Diseases there, in 2004. Professor Schellong was appointed Professor of Internal Medicine/Angiology of the medical faculty of the Technical University of Dresden in 2004. Currently, he is the Head of internal medicine Department II at the Dresden-Friedrichstadt Municipal Hospital, Dresden in Germany. For more than 42 years he is the CEO of the Deutsche Gesellschaft für Angiologie, currently he is President elected for the term 2018-2019. Professor Schellongs fields of investigation include: venous thromboemobolism diagnostic modalities of deep-vein thrombosis (DVT) and pulmonary embolism (PE); prolonged DVT prophylaxis; ambulatory care of DVT patients, as well as arterial disease; measurement of muscle blood flow in peripheral arterial obstructive disease (PAOD); basics of doppler measurement of arterial resistance and stenosis; serodiagnosis and clinical course of systemic vasculitis. Sebastian Schellong has been involved in various committees for the pivotal clinical trials with new direct oral anticoagulants both for prophylaxis and treatment. He lectures internationally, and has published more than 250 papers in international peer-reviewed journals.
PORTO VASCULAR CONFERENCE 2018

17–19 May

“Latest Advances on Venous and Arterial Diseases”

Chairman: Armando Mansilha MD, PhD, FEBVS
Angiology and Vascular Surgery

Auditorium
Center for Medical Research
Faculty of Medicine of the University of Porto

**Zusammenstellung:** Xarelto® 15 mg/20 mg Filmtabletten, Wirksalz: 15 mg Rivaroxaban, 20 mg Ximelagatran. 


**Wirkstoff:** Rivaroxaban. 

**Sonstige Bestandteile:** Mikrokristalline Cellulose, Croscarmellose-Natrium, Lactose-monohydrat, Hypermagnesiussulfat, Magnesiumstearat, Laktulose, Saccharose, Crospovidon, Xanthan-Gummi, Maltodextrin, Pregelatinisierter Trockenextrakt von der Chairzucht von Alcaligenes faecalis, Phosphatbuffer 0,2 Molar bei pH 7,4, Wasser. 

**Monohydrat, Hypromellose, Natriumdodecylsulfat, Magnesiumstearat, Macrogol (3350), Titanoxid (E171), Eisenoxid (E172).** 

**Zusammensetzung:** 15 mg/20 mg Rivaroxaban. 

**Vorsichtsmaßnahmen bei speziellen Patientenkreisen:** Die Behandlung von Rivaroxaban wird nicht empfohlen bei Patienten mit einer schweren Nierenfunktionsstörung (Kreatinin-Clearance <30 ml/min). 

**Vorsichtsmaßnahmen bei speziellen Patientenkreisen:** Die Behandlung von Rivaroxaban wird nicht empfohlen bei Patienten mit einer schweren Nierenfunktionsstörung (Kreatinin-Clearance <30 ml/min). 

**Gegenanzeigen:** Angioödeme u. allergische Ödeme, Cholestase und Hepatitis (einschließlich hepatozelluläre Schädigung), Thrombozytopenie, Polyneuropathie, Pseudoaneurysma. 

**Selten:** Gelbsucht, Blutung in einen Muskel, lokale Ödeme, Anstieg von konjugiertem Bilirubin, vaskuläres alkalischer Phosphatase im Blut, LDH, Lipase, Amylase, GGT, Leberfunktionsstörung, Unwohlsein, Anstieg von: Bilirubin, Transaminasenanstieg, postoperative Blutungen, gastrointestinale Blutungen, gastrointestinale und abdominale Schmerzen, Dyspepsie, Übelkeit, Verstopfung, Durchfall, Erbrechen, Angioödeme u. allergische Ödeme, Cholestase und Hepatitis (einschließlich hepatozelluläre Schädigung), Thrombozytopenie, Polyneuropathie, Pseudoaneurysma. 

**Vorsichtsmaßnahmen bei speziellen Patientenkreisen:** Die Behandlung von Rivaroxaban wird nicht empfohlen bei Patienten mit einer schweren Nierenfunktionsstörung (Kreatinin-Clearance <30 ml/min). 

**Gegenanzeigen:** Angioödeme u. allergische Ödeme, Cholestase und Hepatitis (einschließlich hepatozelluläre Schädigung), Thrombozytopenie, Polyneuropathie, Pseudoaneurysma. 

**Selten:** Gelbsucht, Blutung in einen Muskel, lokale Ödeme, Anstieg von konjugiertem Bilirubin, vaskuläres alkalischer Phosphatase im Blut, LDH, Lipase, Amylase, GGT, Leberfunktionsstörung, Unwohlsein, Anstieg von: Bilirubin, Transaminasenanstieg, postoperative Blutungen, gastrointestinale Blutungen, gastrointestinale und abdominale Schmerzen, Dyspepsie, Übelkeit, Verstopfung, Durchfall, Erbrechen, Angioödeme u. allergische Ödeme, Cholestase und Hepatitis (einschließlich hepatozelluläre Schädigung), Thrombozytopenie, Polyneuropathie, Pseudoaneurysma. 

**Vorsichtsmaßnahmen bei speziellen Patientenkreisen:** Die Behandlung von Rivaroxaban wird nicht empfohlen bei Patienten mit einer schweren Nierenfunktionsstörung (Kreatinin-Clearance <30 ml/min). 

**Gegenanzeigen:** Angioödeme u. allergische Ödeme, Cholestase und Hepatitis (einschließlich hepatozelluläre Schädigung), Thrombozytopenie, Polyneuropathie, Pseudoaneurysma. 

**Selten:** Gelbsucht, Blutung in einen Muskel, lokale Ödeme, Anstieg von konjugiertem Bilirubin, vaskuläres alkalischer Phosphatase im Blut, LDH, Lipase, Amylase, GGT, Leberfunktionsstörung, Unwohlsein, Anstieg von: Bilirubin, Transaminasenanstieg, postoperative Blutungen, gastrointestinale Blutungen, gastrointestinale und abdominale Schmerzen, Dyspepsie, Übelkeit, Verstopfung, Durchfall, Erbrechen, Angioödeme u. allergische Ödeme, Cholestase und Hepatitis (einschließlich hepatozelluläre Schädigung), Thrombozytopenie, Polyneuropathie, Pseudoaneurysma.
GOLD

BARD  
Cook Medical  
Getinge

Medtronic  
Vascutek Terumo

SILVER

Amgen  
Bayer  
Boston Scientific  
Gore

Philips  
SilkRoad Medical  
Spectranetics  
Ziehm Imaging

BRONZE

Bentley  
Medistim  
Mentice

EXHIBITOR

Abbott  
aimecs medical solutions  
Brainlab  
Bristol-Myers Squibb

Cardinal Health  
Daiichi-Sankyo  
Endologix  
GE Healthcare

Jotec  
Lamed Solutions for Life  
Moeller Medical  
NicolaI

Pharmore  
Piuro Imaginc  
2D Global Research & Development  
Siemens Healthineers

Terumo  
Veryan

ACKNOWLEDGEMENTS